Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at or call 800-767-3771 ext.  9339.

Sanofi (SNY - Analyst Report) recently announced that a decentralized marketing authorization application (MAA) for its quadrivalent flu vaccine, Vaxigrip, has been accepted for review in the EU.

The Vaxigrip quadrivalent formulation contains two strains of influenza A and two strains of influenza B, thus providing it with an edge over the currently available trivalent Vaxigrip version. Vaxigrip trivalent contains two strains of influenza A and one strain of influenza B.

We note that Sanofi’s influenza vaccine portfolio also includes Fluzone. Sanofi is looking to get the quadrivalent formulation of Fluzone approved in the US. To achieve this objective, the company submitted a Supplemental Biologics License Application (sBLA) with the US Food and Drug Administration (FDA) last year. A final decision from the FDA is expected in the second quarter of 2013.

We note that in the US, AstraZeneca’s (AZN - Analyst Report) FluMist Quadrivalent and GlaxoSmithKline (GSK - Analyst Report) Fluarix already approved.

We note that Sanofi possesses one of the world’s leading vaccine operations, with total sales of €3.9 billion in 2012. The company’s portfolio includes pediatric vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines. Sanofi also has a strong position in both seasonal and pre-pandemic influenza vaccines.

Sanofi continues to expand its vaccine business. We like what we see in the vaccine pipeline and expect a significant ramp in vaccine sales over the next several years. Sanofi has beefed up its Chinese presence with a new vaccine manufacturing facility in Shenzhen.

Sanofi carries a Zacks Rank #4 (Sell) in the short run. Right now, Allergan Inc. (AGN - Analyst Report) looks more attractive in the pharma space with a Zacks Rank #2 (Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ANI PHARMACE ANIP 29.54 +15.62%
FEDERATED NA FNHC 20.70 +4.18%
ALLIANCE FIB AFOP 17.95 +3.64%
GENTHERM INC THRM 36.91 +2.95%
GREEN PLAINS GPRE 29.78 +2.87%